Abstract:Purpose/Objective(s) Clinically relevant biomarkers for anti-programmed death (PD)-1 therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are limited to PD ligand-1 combined proportion score (PD-L1 CPS) on tumor biopsies. Cytokines are soluble proteins that act as a bridge between innate immunity, inflammation, and cancer. Given the interest in circulating biomarkers, this study sought to evaluate pre- and post-treatment serum cytokine expression signatures in R/M HNSCC treated with anti-PD-1 therapy. Materials/Methods In this ongoing, prospective multi-center study, 33 paired pre- and post-treatment (cycle 2 day 1) blood samples were analyzed for 92 cytokine biomarkers (Olink Target 96 Immuno-Oncology) in patients with R/M HNSCC on anti-PD-1-based therapy. Associations between pre-treatment, post-treatment, and change of pre- to post-treatment cytokine levels, overall survival (OS), and progression-free survival (PFS) were assessed using Kaplan-Meier curves, multivariable Cox proportional hazards (adjusted for age, sex, smoking, PD-L1 CPS, ECOG performance status, and platelet count), and unsupervised clustering analyses. Results There was a statistically significant association between pre-treatment cytokine expression signature, and both immune composition (e.g., relative fractions of circulating immune cell subtypes) and platelet count. Comparing pre- and post-treatment samples, expression levels of most cytokines exhibited a statistically significant increase (p <0.05). In pre-treatment samples, several cytokines exhibited nominally statistically significant associations (p < 0.05) with both OS and PFS in multivariable model. Similar results were seen in analyses of serum cytokines with PFS in post-treatment samples. Machine learning analysis using Elastic Net models identified a panel of cytokines (CD40.L, EGF, ANGPT1, MCP.4, CXCL1, IL10) that predicted survival with high prognostic performance (Cross Validated C-index of 0.75) in pre-treatment samples. Notably, a different panel of cytokines (ANGPT1, IL10, FGF2, TNFSF14, Gal.1, HGF, PTN, VEGFA, CCL20) predicted survival with even higher prognostic performance (Cross Validated C-index of 0.90) in post-treatment samples. Unsupervised clustering analysis based on the change in pre- versus post-treatment cytokine expression identified two subgroups which differed in their survival trajectories (log-rank p =0.09 and 0.01 for OS and PFS, respectively), where the subgroup with smaller changes in serum cytokine levels was associated with higher survival. Conclusion Our results highlight the potential prognostic and predictive value of serum cytokine expression signatures in R/M HNSCC treated with anti-PD-1 therapy and underscore the importance of longitudinal on-treatment assessments in peripheral blood.

Pre- and Post-treatment Serum Cytokine Expression Signatures and Survival Outcomes in Patients with Head and Neck Squamous Cell Cancer on Anti-PD-1 Therapy

B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma

Anti-PD-(L)1-Based Neoadjuvant Therapy in Head and Neck Carcinoma: a Meta-analysis of Prospective Clinical Trials.

Interrogating the tumor microenvironment (TME) in patients (pts) with head and neck mucosal squamous cell carcinoma (HNmSCC) treated with programmed death-1 (PD-1) inhibitors.

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker Correlatives

Prognostic Role of Serum Cytokines Level in Non-Small Cell Lung Cancer Patients with Anti-Pd-1 and Chemotherapy Combined Treatment

Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy

Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab

Correlation of Constitutive PD-1 Resistance in HNC with GM-CSF Expression and Presence of Myeloid Derived Suppressor Cells (Mdscs).

Dynamics of Serum Tumor Markers Can Serve As a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome

Combined Positive Score and Cisplatin Sensitivity Are Prognostic Factors for Response to Nivolumab Therapy for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

Immune signatures of patients with advanced non-small-cell lung cancer for efficacy prediction after immunotherapy

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors